Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study-Reference-Cited by-同舟云学术

Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study

Published:2022-04 Issue:4 Volume:33 Page:850-866
ISSN:1046-6673
Container-title:Journal of the American Society of Nephrology
language:en
Short-container-title:JASN

Author:

Fishbane Steven,Pollock Carol A.,El-Shahawy Mohamed,Escudero Elizabeth T.,Rastogi Anjay,Van Bui Pham,Frison Lars,Houser Mark,Pola Maksym,Little Dustin J.,Guzman Nicolas,Pergola Pablo E.

Funder

AstraZeneca

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Nephrology,General Medicine

Reference28 articles.

1. Physiology and pathophysiology of renal erythropoietin-producing cells;Shih;J Formos Med Assoc,2018

2. Anaemia in kidney disease: Harnessing hypoxia responses for therapy;Koury;Nat Rev Nephrol,2015

3. Iron deficiency anemia in chronic kidney disease;Gafter-Gvili;Acta Haematol,2019

4. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease;Thorp;Nephrology (Carlton),2009

5. Transfusion burden among patients with chronic kidney disease and anemia;Lawler;Clin J Am Soc Nephrol,2010

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease;NEJM Evidence;2024-08-27

2. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease;Biomedicines;2024-08-18

3. A real-world analysis of roxadustat effectiveness and safety in managing renal anemia among patients on maintenance hemodialysis: An observational study;Medicine;2024-08-02

4. Transfusion-induced HLA sensitization in wait-list patients and kidney transplant recipients;Kidney International;2024-08

5. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systematic review and network meta-analysis;Frontiers in Pharmacology;2024-07-10